Stock Scorecard
Stock Summary for Illumina Inc (ILMN) - $121.05 as of 4/26/2024 3:21:56 PM EST
Total Score
6 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ILMN
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ILMN
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ILMN
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for ILMN
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for ILMN
Financial Details for ILMN
Company Overview |
|
---|---|
Ticker | ILMN |
Company Name | Illumina Inc |
Country | USA |
Description | Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California. |
Sector Name | LIFE SCIENCES |
Industry Name | LABORATORY ANALYTICAL INSTRUMENTS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/16/2024 |
Stock Price History |
|
Last Day Price | 121.05 |
Last Day Price Updated | 4/26/2024 3:21:56 PM EST |
Last Day Volume | 0 |
Average Daily Volume | 1,578,251 |
52-Week High | 213.91 |
52-Week Low | 89.00 |
Last Price to 52 Week Low | 36.01% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 29.03 |
Sector PE | 56.64 |
5-Year Average PE | 78.29 |
Free Cash Flow Ratio | 18.29 |
Industry Free Cash Flow Ratio | 102.58 |
Sector Free Cash Flow Ratio | 30.65 |
Current Ratio Most Recent Quarter | 1.66 |
Total Cash Per Share | 6.62 |
Book Value Per Share Most Recent Quarter | 36.13 |
Price to Book Ratio | 3.52 |
Industry Price to Book Ratio | 801.96 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 4.49 |
Industry Price to Sales Ratio Twelve Trailing Months | 4.44 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
Total Shares Outstanding | 159,255,000 |
Market Capitalization | 19,277,817,750 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 2.17% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | -96.50% |
Annual Earnings Growth | 73.64% |
Reported EPS 12 Trailing Months | -7.34 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | 0.87 |
Net Income Twelve Trailing Months | -1,160,000,000 |
Net Income Past Year | -1,161,000,000 |
Net Income Prior Year | -4,404,000,000 |
Quarterly Revenue Growth YOY | 3.60% |
5-Year Revenue Growth | 6.21% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 1,054,000,000 |
Total Cash Past Year | 1,054,000,000 |
Total Cash Prior Year | 2,037,000,000 |
Net Cash Position Most Recent Quarter | -435,000,000 |
Net Cash Position Past Year | -435,000,000 |
Long Term Debt Past Year | 1,489,000,000 |
Long Term Debt Prior Year | 2,735,000,000 |
Total Debt Most Recent Quarter | 1,489,000,000 |
Equity to Debt Ratio Past Year | 0.79 |
Equity to Debt Ratio Most Recent Quarter | 0.79 |
Total Stockholder Equity Past Year | 5,745,000,000 |
Total Stockholder Equity Prior Year | 6,599,000,000 |
Total Stockholder Equity Most Recent Quarter | 5,745,000,000 |
Options |
|
Put/Call Ratio | 0.98 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -3.76 |
MACD Signal | -3.58 |
20-Day Bollinger Lower Band | 119.71 |
20-Day Bollinger Middle Band | 134.07 |
20-Day Bollinger Upper Band | 148.42 |
Beta | 1.19 |
RSI | 42.83 |
50-Day SMA | 149.93 |
200-Day SMA | 280.90 |
System |
|
Modified | 4/27/2024 3:11:26 AM EST |